IShares struggles to pay out dividends that qualify for the 15% tax rate.
Even under a new name the former KFx still faces questions about its refining process.
A small maker of medical devices used in back surgery has a healthy prognosis.
Claymore Securities adds five funds to a rapidly expanding ETF field.
With its latest ETF launch, FTSE parts with the NYSE in favor of the Nasdaq.
Three months after WisdomTree's launch, LaBranche is replaced as its specialist.
A gaming company's recent rise should make even gamblers nervous.
A new ETF will allow average investors to get in on the private-equity action.
A boardroom brawl at a tiny drug developer offers an intriguing entry point for risk-takers.
Exchange-traded notes promise tax savings and fewer tracking errors, but risks abound.